🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Synendos is thrilled to announce the formation of the Scientific Advisory Board composed of prominent scientists and clinicians with significant CNS expertise. #CNS #endocannabinoid #neurology #stressdisorders #neuropsychiatric 👉Full press release: synendos.com/post/october-2…

We are hiring! We are looking for a Head of Preclinical and Translational Neuropharmacology. 👉To apply, check our website: synendos.com/openpositions

Accounting for 33% of exports, life science is a major business in Switzerland. Innovation is strongly powered by biotech startups. Meet the 15 companies that scored in the TOP 100 Swiss Startup Award 2021: top100startups.swiss/The-TOP-Swiss-… #TOP100SSU #SwissStartups #Biotech

With the support of #InnoBoosterGRS, Andrea Chicca and his team at synendos are developing breakthrough safe and effective therapies for neuropsychiatric disorders such as anxiety, mood and stress-related disorders. Universität Bern youtu.be/EUbYnqOhu0Y

We are hiring! We are looking for a Head of Translational Neuropharmacology. 👉To apply, check our website: synendos.com/openpositions

Synendos is present at the @SwissBioTech Days 2022! CEO Andrea Chicca will present @Synendos (Tue, 3. May 2:00-2:15 pm) as Emerging Biotech Company. #sbd2022 #neuroscience #endocannabinoid #CNS #biotech

Read about the path that led @NCCR_TransCure and @Gertschlab to launch synendos, an NCCR TransCure spin-off, representing a tangible result of the translational research, in their LAST newsletter #scientificnews #translationalmedicine #biotech #neuroscience #CNS #endocannabinoid

Thank you Innosuisse & Switzerland Global Enterprise for their continued support. We’re excited to be part of the Swiss delegation at #BIO2022 in San Diego on June 13-16, where we are looking forward to expanding our network of partners #biotech #CNS #neuroscience #endocannabinoid #SERIs synendos

CELEBRATING all WINNERS of the #TOP100SSU Swiss Startup Award 2022: top100startups.swiss/award2022 Skribble Sygnum Bank @Synendos @Synthara Terapet @TerraQuantum_AG @Threatray Tinamu Labs TOLREMO therapeutics @TuneInsight TYXIT Audio Visium Volumina Medical @Yokoy_ai @Zytlyn

Meet the synendos team during the #BIOEUROPE 2022 in Leipzig 24 – 26 October at the #SWISSPavilion #SwissBiotech, to discuss our first-in-class therapy to restore the healthy balance of brain physiology #biotech #neuroscience #CNS #endocannabinoid informaconnect.com/bioeurope/

It is a great honor to share that Synendos has been awarded with the prestigious Innosuisse certificate, which indicates readiness for sustainable growths! #swissstartups #biotech #entrepeneurship #award #innovation #CNS #psychiatry #endocannabinoidsystem

Excited to participate at #BIOEuropeSpring 2023 in our hometown Basel, on March 20-22. Looking forward to meeting & connecting with you to discuss our novel approach to restoring physiological brain function. #CNS #neuroscience #endocannabinoid #biotech #startups

Our CEO & CSO Andrea Chicca will be speaking at BIO-Europe Spring 2023, March 21, 14:00 – 14:45 in Basel. He will be the part of session “Navigating the Roadblocks of Biotech Entrepreneurship: Strategies for Startup Success”. Sharing his journey with Synendos Therapeutics AG.

synendos participates to the #BIO2023 International Convention, June 5-8. Meet our CEO/CSO Andrea Chicca and CCO Simon Russell to discuss the innovative approach to restoring brain physiology in #mentalhealth! #CNS #biotech #innovation #endocannabinoidsystem #SERI #neuroscience

Synendos participates to the TOP 100 Swiss Start-ups Public Vote 2023! Support our work in improving mental health care! Voting is open, using your LinkedIn account, at startup.ch/synendos-thera…. #TOP100SSU #BiotechInnovation #endocannabinoidsystem #CNS #entrepreneurship #teamwork

@Synendos is excited to support and participate in the 10th Gordon Research Conferences "Cannabinoids Function in the CNS" from 16-21st July 2023, with a talk from co-founder and scientific advisor member Prof. Jürg Gertsch. #endocannabinoidsystem #CNS #Biotech More info: grc.org/cannabinoid-fu…

@Synendos today announces that co-founder and SAB member Prof. Jürg Gertsch presented groundbreaking findings on an #endocannabinoid transporter at the 10th Gordon Research Conferences, informing and augmenting Synendos' pioneering ECS pipeline development. Read more: synendos.com/post/july-2023…

Meet our CEO, Andrea Chicca, and CCO, Simon Russell, Jefferies London Healthcare Conference next week, 14-16 November. Please get in touch if you would like to meet with the synendos team at this important industry event. #CNS #biotech #neuropsychiatry

We are excited to have received Clinical Trial Authorisation from the European Medicines Agency for our first-in-class Endocannabinoid System (ECS) modulator SYT-510 Learn more:synendos.com/post/january-2… #EndocannabionoidSystem #CentralNervousSystem #CTA #EMA #SERI #neuropsychiatry

@Synendos is excited to announce the publication of the latest article written by Andrea Chicca and Jürg Gertsch, “CNS Drug Discovery in Academia: Where Basic Research Meets Innovation“ on ChemBioChem. #Biotech #Academia #drugdiscovery #ChemBioChem